// STATE LEGISLATION TRACKER

Texas HB 195 — Relating to the regulation of the cultivation, processing, packaging, labeling, distribution, sale, testing, transportat

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Texas
Bill: HB 195
Filed: 2025-07-24
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Texas HB 195 appears to regulate a product supply chain involving cultivation, processing, packaging, labeling, distribution, sale, testing, delivery, dispensing, possession, and use. Based on the available title and missing action data, it does not show clear relevance to compounded peptides, off-label peptide prescribing, telehealth peptide care, NP/naturopath scope, FDA 503A/503B compounding, or prescription monitoring for peptides.

Key Points

No clear peptide-specific access change is visible from the title
No clear impact on compounded peptide prescribing or pharmacy compounding
No clear telehealth, NP, or naturopathic scope change is shown
Could involve controlled substances, but peptide relevance is not shown

What to Watch For

Note Full bill text is needed to confirm whether any controlled-substance or dispensing rules affect peptide care.

Note Latest action is unavailable, so the bill's process status cannot be confirmed from the provided source.

Where the Bill Stands

The provided source reports that the latest action could not be refetched, so the bill's current status is unknown.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws